Ho PJ, et al. - Given the influence of timely management on breast cancer-specific survival may vary by tumor stage, so, researchers assessed how delayed first treatment influences overall survival across different tumor stages. Among patients with invasive nonmetastatic breast cancer who underwent operation ≤ 90 days after diagnosis, the influence of delayed adjuvant treatments on survival was also assessed. In this population-based investigation, overall 11,175 breast cancer patients were included. Among those, deaths of 2,318 (20.7%) were reported (median overall survival = 7.9 years). Experts found that the proportion of delayed first treatment (> 30 days postdiagnosis) was highest in those having noninvasive breast cancer (61%), followed by metastatic breast cancer (50%) and invasive nonmetastatic breast cancer (22%). Among patients with invasive nonmetastatic and metastatic breast cancer, a link was identified between delayed first treatment (> 90 vs ≤ 30 days postdiagnosis) and worse overall survival. In those with invasive nonmetastatic, worse survival related to delayed adjuvant treatment (> 90 vs 31-60 days postsurgery) was reported. Findings highlighted the likely viability of a longer time to first treatment (31-90 days postdiagnosis) for more extensive diagnostic workup as well as the patient-doctor decision-making process, with no compromise in survival. However, taking into consideration patients’ preferences as well as anxiety status is a necessity.